AroCell's board of directors proposes to the AGM that the parent company change its name to IDL Diagnostics AB

MARKN.

The board proposes to the annual general meeting (AGM) that AroCell AB changes its name to IDL Diagnostics AB. The main purpose of the name change is to create a stronger connection to the diagnostics industry.

The board and management see several advantages with the proposed name change:

· It becomes clear that we are active in the field of diagnostics when we add "Diagnostics" to the company name.
· IDL Biotech is a well-known name for our partners, customers, clinics, and other stakeholders.
· A clear connection to IDL Biotech and its product portfolio is established, which today accounts for most of our revenue and operations.

The new name will serve as a collective name for all the company's operations and products, while clarifying the company's direction and providing a strong foundation for the company's continued growth.

"I see great value in highlighting IDL as a brand because it is a well-established name in the industry. It will be helpful in the growth journey that lies ahead for all the group's products," says Anders Hultman, CEO of AroCell.

Datum 2025-04-11, kl 09:00
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!